Neutralizing antibody is one of the most effective interventions for acute pathogenic
infection. Currently, over three million people have been identified for SARS-CoV-2 infection …

Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide
range of biomedical applications involving novel coronavirus disease (COVID-19) …

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-
China. Owing to a high rate of transmission from human to human, the new virus called …

Monoclonal antibodies (mAbs) that are specific to SARS-CoV-2 can be useful in diagnosing,
preventing, and treating the coronavirus (COVID-19) illness. Strategies for the high …

Background Since the outbreak of coronavirus disease (COVID-19), the high infection rate
and mutation frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The global pandemic of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in widespread social and economic disruption …

The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here,
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …

As new variants of SARS-CoV-2 continue to emerge, it is important to assess the cross-
neutralizing capabilities of antibodies naturally elicited during wild type SARS-CoV-2 …

After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have
been developed for the prophylactic and therapeutic purposes. However, few …

Novel coronavirus pneumonia, also known as coronavirus disease 2019 (COVID-19), is
caused by sub-severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) …